Related Experiment Video

Updated: Jul 19, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

485

Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway

Chunshui Ye1, Wei Chong1,2,3, Yuan Liu1

  • 1Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong University Jinan, Shandong, China.

American Journal of Cancer Research
|August 10, 2023
PubMed

Insights

Low expression of LRP1B enhances lung adenocarcinoma (LUAD) malignancy by activating inflammation via the IL-6-JAK-STAT3 pathway. This study identifies LRP1B as a tumor suppressor in LUAD, crucial for genomic stability.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung adenocarcinoma (LUAD) is a prevalent cancer type.
  • LRP1B is recognized as a potential cancer suppressor.
  • The role of LRP1B in LUAD progression remains underexplored.

Purpose of the Study:

  • To investigate the biological functions and molecular mechanisms of LRP1B in LUAD.
  • To determine the impact of LRP1B expression levels on LUAD cell malignancy.
  • To elucidate the signaling pathways influenced by LRP1B in LUAD.

Main Methods:

  • Comparative analysis of LRP1B expression in LUAD and normal tissues.
  • Experimental manipulation of LRP1B expression (knockdown) in LUAD cells.
  • Genomic instability assessment, transcriptomic data analysis (bulk and cell-line), and pathway enrichment analysis.
  • Validation of signaling pathway activation using ELISA, PCR, and Western Blot (WB).

Main Results:

  • LRP1B expression is significantly lower in LUAD tissues compared to normal tissues.
  • LRP1B knockdown increases LUAD cell malignancy and genomic instability, correlating with aneuploidy and inflammation.
  • Downregulation of LRP1B activates inflammation-related pathways, including IL-6-JAK-STAT3, and elevates IL-6 and IL-8 secretion.

Conclusions:

  • LRP1B functions as a tumor suppressor gene in LUAD.
  • Reduced LRP1B expression promotes LUAD progression by inducing inflammation through the IL-6-JAK-STAT3 signaling pathway.
  • LRP1B status may serve as a potential biomarker or therapeutic target in LUAD.
Keywords:
IL-6JAK-STAT3LRP1BLUADinflammation

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

960

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K